Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2019 After Market Close on June 27, 2019

On June 24, 2019 Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, reported that it will report financial results for the quarter and fiscal year (FY) ended April 30, 2019 on June 27, 2019 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time) (Press release, Avid Bioservices, JUN 24, 2019, View Source [SID1234539008]). Members of Avid’s senior management will discuss financial results for the quarter and FY ended April 30, 2019 and review recent corporate developments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To listen to the live webcast, or access the archived webcast, please visit: View Source

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.

8-K – Current reportEntry into a Material Definitive Agreement.

On June 24, 2019, Xenetic Biosciences, Inc. (the "Company"), in connection with its previously announced reverse stock split, reported that it entered into a consent agreement (the "Consent Agreement") with certain holders (the "Holders") of warrants to purchase shares of the Company’s common stock whose consent was required to effect the reverse stock split (Filing, 8-K, Xenetic Biosciences, JUN 24, 2019, View Source [SID1234537830]). In consideration of the Holders’ consent, the Company agreed to issue the Holders warrants (the "Consent Warrants") to purchase an aggregate of 100,000 shares of the Company’s common stock, on a pre-split basis, at an exercise price per share based on a volume weighted average price for the five trading days following the effectiveness of the reverse stock split, as further described in the Consent Warrants. On a post-split basis, the Company will issue Consent Warrants to purchase an aggregate of 8,335 shares of Company common stock to the Holders. Copies of the Consent Agreement and a form of the Consent Warrants are filed as Exhibit 10.1 and Exhibit 4.1 to this report and are incorporated herein by reference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bioasis Announces Allowances of Patent Applications in the U.S. and Europe Relating to xB3 Platform Technology and Key Therapeutic Indications

On June 24, 2019 Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, reported that the U.S. Patent and Trademark Office ("USPTO") and the European Patent Office ("EPO") have issued allowances of patent applications relating to xB3 technology (Press release, biOasis, JUN 24, 2019, View Source [SID1234537254]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Both the USPTO and EPO have issued allowances of the Company’s patent applications relating to iduronate-2-sulfatase ("IDS") polypeptide / xB3 conjugates. The patent applications relate to the IDS/xB3 fusion conjugates as well as pharmaceutical compositions containing the fusion conjugates. The IDS/xB3 conjugates may be used in treating lysosomal storage diseases such as Hunter Syndrome.

The EPO has issued an allowance of the Company’s patent application relating to trastuzumab/xB3 fusion conjugates. The patent application relates to the trastuzumab/xB3 fusion conjugates as well as pharmaceutical compositions containing the fusion conjugates. The trastuzumab/xB3 conjugates may be used in treating a variety of diseases, for example, a HER2-overexpressing metastatic breast cancer.

"We are excited about the issuance of allowance of these patent applications by the USPTO and EPO, which enhance the strength of our intellectual property protection around our core assets, especially with respect to our lead program xB3-001, potential treatments for lysosomal storage disorders and our commercial licensing strategy," said Company Chair and Chief Executive Officer, Deborah Rathjen, Ph.D. "These patents reaffirm the overall value of Bioasis’ xB3 platform technology as we work to advance our programs for difficult-to-treat diseases of the central nervous system by delivering therapeutics across the blood-brain barrier."

City of Hope Reveals Its Bold Vision to Invest More Than $1B for World-Class Cancer Care at FivePoint Gateway in Orange County

On June 24, 2019 City of Hope, a world-renowned independent research and treatment center for cancer, reported plans to invest more than $1B to develop and support a new comprehensive cancer campus at FivePoint Gateway in Orange County, accelerating highly specialized cancer care, phase I-III clinical trials, and precision medicine and early detection to the nation’s sixth most populous county (Press release, City of Hope, JUN 24, 2019, View Source [SID1234537253]). This unprecedented initiative in Orange County is part of City of Hope’s commitment to speeding pioneering treatments and scientific breakthroughs to the people who need them today.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Last year, City of Hope and FivePoint announced their partnership to build a $200 million, 73,000-square-foot cancer center in FivePoint’s Great Park Neighborhoods by 2025. As planning progressed, FivePoint and City of Hope expanded their vision for the Great Park as a model community of the future with easily accessible world-class health and wellness as a core offering. In line with this vision, City of Hope significantly increased its investment with a focus on highly specialized cancer care, research and lifesaving treatments.

Now a space as big as the vision, the cancer campus on approximately 11 acres of land at FivePoint Gateway in Irvine will include an approximately 190,000-square-foot building that will be a center of innovative cancer research and treatments. This increased investment cuts City of Hope’s time to build the new campus by half, with the center expected to open its doors in 2021.

City of Hope officials cite several reasons for an expanded presence in the region. Nearly 20% of residents leave the area for advanced care, with many heading to City of Hope’s main campus in Duarte, California – an up to two-hour commute away. In addition, despite its reputation for healthy living, Orange County is not immune from the one-in-three national statistic for cancer incidence. In fact, the cancer incidence rate in the county is projected to increase by 18% over the next decade. Cancer risk increases with age and the county’s population is aging faster than the U.S. average.

City of Hope is answering the call to extend its personalized care, outstanding research and lifesaving treatments closer to home with the same sense of urgency as its scientists who find and deliver cures. The City of Hope cancer campus is planned to include:

Orange County’s only specialty hospital dedicated solely to treating and curing cancer.
An outpatient cancer center offering diagnostic imaging and screenings, precision medicine and early detection, medical oncology, chemotherapy, radiation therapy, surgical oncology and ambulatory surgery.
A clinical research center offering phase I-III clinical trials.
Personalized supportive care services that include palliative care physicians, psychiatrists, social workers and others who partner with patients and their families to address the many physical and emotional issues that can arise during and after treatment. City of Hope is the model for other institutions across the country.
Access to a wide range of solid tumor and blood cancer specialists dedicated to finding the best treatments for each patient.
This campus will be an extension of City of Hope in Duarte, providing access to highly specialized cancer experts and treatment for the most complex cases, such as bone marrow transplants, stem cell transplants and CAR T cell therapy.

City of Hope Orange County will include additional clinical locations that will provide medical oncology and infusion services, ensuring easy access to care throughout the region. As previously announced, City of Hope is planning to open its Newport Beach facility later this year, providing residents with a more convenient way to receive leading-edge medicine.

Science that is saving lives:

Each year, more than 100 million people benefit from discoveries made at City of Hope and patients from around the world are treated at its main campus in Duarte and at the 30 locations in its clinical network.
City of Hope is currently conducting more than 500 clinical trials and its internationally respected scientists and clinical experts collaborate across disciplines to turn science into practical benefit.
City of Hope’s research has saved lives around the world; four of the most widely used cancer drugs are based on technology pioneered by City of Hope, and the organization is a pioneer in bone marrow and stem cell transplants.
City of Hope is one of only 49 comprehensive cancer centers in the nation, as designated by the National Cancer Institute.
As one of the nation’s leading independent research clinical enterprises, City of Hope’s clinical network also includes three good manufacturing practice (GMP) facilities and, through an affiliation with Translational Genomics Research Institute (TGen), advances in genomics technologies for the application of precision medicine.
With City of Hope’s unique approach to care, physicians and scientists are connected through a powerful research environment that speeds the development of new drugs and interventions to the bedside, allowing patients to receive the latest treatments in cancer care.
Supporting quotes:

Robert Stone, president and CEO, City of Hope

"This is a time of great promise and innovation in cancer research and care, and we are bringing that excitement and expertise to Orange County. City of Hope is dramatically expanding to provide a cancer network of unparalleled scale for this community. It will be a nexus of service, science and care. It is made possible by our partnership with FivePoint Holdings and a strong community of philanthropic supporters in Orange County and beyond, who stand shoulder to shoulder with us in our determination to eradicate cancer."

Annette M. Walker, president, City of Hope Orange County

"We’ve spent the last year listening intently to the people in Orange County and identifying how we can contribute to meeting both the present and future community needs. It became evident that we needed to bring our highly specialized treatments as soon as possible. We’re delivering on our promise and opening our doors faster to alleviate the unnecessary hardships on patients and their families. Residents soon will be able to access City of Hope’s latest and most advanced therapies closer to home."

Michael Caligiuri, M.D., president, City of Hope National Medical Center, and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair in Honor of Alexandra Levine, M.D.

"City of Hope researchers are working every day to speed novel cancer drugs and immune cell therapies from our laboratories into the clinic for our patients. With more than 500 clinical trials and world-class experts across cancer types, City of Hope is changing the landscape of cancer care. Our expansion into Orange County provides greater access to our highly specialized medical expertise and to the next generation of promising cures and treatments."

Emile Haddad, Chairman and CEO, FivePoint Holdings LLC

"At FivePoint, we believe in creating places that offer equal access to the most important aspects of our lives. Building a sustainable society that moves humanity forward goes beyond building structures for housing, schools and recreation. It includes creating spaces where the body, mind and soul get strengthened together. Because it takes a village to build a community, FivePoint is constantly searching for partners that innovate and shape the future of how people will live. As FivePoint considered the importance of wellness, it was clear that City of Hope is the ideal partner to bring world-class cancer treatment and research to Irvine and Orange County."

For updates on the initiative, or to become a volunteer or philanthropic partner of City of Hope Orange County, go to CityofHope.org/OC.

Personalis Announces Closing of Initial Public Offering and Exercise in Full of Over Allotment Option

On June 24, 2019 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported the closing of its initial public offering of 9,109,725 shares of common stock at a public offering price of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,188,225 additional shares of common stock (Press release, Personalis, JUN 24, 2019, View Source [SID1234537252]). All of the shares of common stock were offered by Personalis. Personalis estimates net proceeds from the offering to be approximately $140.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. The company’s stock began trading on The Nasdaq Global Market on June 20, 2019 under the trading symbol "PSNL."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley, BofA Merrill Lynch and Cowen acted as joint book-running managers of the offering. Oppenheimer & Co. Inc. acted as co-manager of the offering.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission and was declared effective on June 19, 2019. A copy of the final prospectus relating to this offering may be obtained, when available, from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at [email protected]; BofA Securities, Inc., Attention: Prospectus Department, NC1‐004‐03‐43, 200 North College Street, 3rd floor, Charlotte, NC 28255‐0001, or by emailing [email protected]; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 631‐274‐2806.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.